A Comparative Study of Levocetirizine Loaded Vesicular and Matrix Type System for Topical Application: Appraisal of Therapeutic Potential against Atopic Dermatitis

Bambusae caulisin Liquamen (BCL), traditional herbal medicine used in East Asia, is known to have antioxidative and immune-regulating properties. We hypothesized that the potential antioxidant effects of BCL might suppress the production of thymus and activation-regulated chemokine (TARC) and macrophage-derived chemokine (MDC) in human keratinocytes (HaCaT cell). The immune-regulating effect of BCL was demonstrated by antioxidant capacity using DPPH analysis and DCFH-DA analysis. We found that BCL had strong ROS scavenge effect in HaCaT cell. BCL also showed suppression of IFN-γ-induced expression of TARC and MDC, activation of NF-κB, and, moreover, significant block of IFN-γ-induced degradation and phosphorylation of IκB. However, it had no effects on phosphorylation of p38 MAPK. Collectively, these results suggest that BCL may have a therapeutic potential on skin disease such as atopic dermatitis by inhibiting Th2 chemokines which is due, at least in part, to its antioxidant capacities.

Download Full-text

Effect of residual Doppler averaging on the probe absorption in cascade type system: A comparative study

Chinese Physics B ◽

10.1088/1674-1056/27/9/094204 ◽

2018 ◽

Vol 27 (9) ◽

pp. 094204 ◽

Cited By ~ 1

Author(s):

Suman Mondal ◽

Arindam Ghosh ◽

Khairul Islam ◽

Dipankar Bhattacharyya ◽

Amitava Bandyopadhyay

Keyword(s):

Comparative Study ◽

Type System ◽

System A ◽

Probe Absorption ◽

Cascade Type

Download Full-text

Comparative Study on the Inhibitory Effects of Topical Application and Feeding of Different Egyptian Garlic Extracts on Chemically Induced Skin Tumors

Journal of Medical Sciences(Faisalabad) ◽

10.3923/jms.2001.81.86 ◽

2001 ◽

Vol 1 (2) ◽

pp. 81-86 ◽

Cited By ~ 1

Author(s):

M.M. El- Mofty ◽

A.E. Essawy ◽

M.H. Shwaireb ◽

A.M. Rizk ◽

J.M. Sorour ◽

...

Keyword(s):

Comparative Study ◽

Topical Application ◽

Skin Tumors ◽

Inhibitory Effects ◽

Chemically Induced

Download Full-text

Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis

Science Translational Medicine ◽

10.1126/scitranslmed.aax2945 ◽

2019 ◽

Vol 11 (515) ◽

pp. eaax2945 ◽

Cited By ~ 29

Author(s):

Yi-Ling Chen ◽

Danuta Gutowska-Owsiak ◽

Clare S. Hardman ◽

Melanie Westmoreland ◽

Teena MacKenzie ◽

...

Keyword(s):

Atopic Dermatitis ◽

Therapeutic Potential ◽

Neutrophil Migration ◽

Neutrophil Infiltration ◽

Severity Index ◽

Fundamental Biology ◽

Targeted Inhibition

Targeted inhibition of cytokine pathways provides opportunities to understand fundamental biology in vivo in humans. The IL-33 pathway has been implicated in the pathogenesis of atopy through genetic and functional associations. We investigated the role of IL-33 inhibition in a first-in-class phase 2a study of etokimab (ANB020), an IgG1 anti–IL-33 monoclonal antibody, in patients with atopic dermatitis (AD). Twelve adult patients with moderate to severe AD received a single systemic administration of etokimab. Rapid and sustained clinical benefit was observed, with 83% achieving Eczema Area and Severity Index 50 (EASI50), and 33% EASI75, with reduction in peripheral eosinophils at day 29 after administration. We noted significant reduction in skin neutrophil infiltration after etokimab compared with placebo upon skin challenge with house dust mite, reactivity to which has been implicated in the pathogenesis of AD. We showed that etokimab also inhibited neutrophil migration to skin interstitial fluid in vitro. Besides direct effects on neutrophil migration, etokimab revealed additional unexpected CXCR1-dependent effects on IL-8–induced neutrophil migration. These human in vivo findings confirm an IL-33 upstream role in modulating skin inflammatory cascades and define the therapeutic potential for IL-33 inhibition in human diseases, including AD.

Download Full-text